目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T75009 | |||
PPARγ/GR modulator 1 是一种口服活性的 PPARγ和糖皮质激素受体 (GR) 的双动激动剂,Ki 值分别为 3.3 和 33.6 μM。PPARγ/GR modulator 1 可用于研究代谢疾病,例如糖尿病。 | |||
T0334 | Ferroptosis TRP/TRPV Channel PPAR Autophagy | ||
Rosiglitazone (BRL49653) 是一种 PPARγ 激动剂、TRPC5 激活剂和 TRPM3 抑制剂,具有口服活性。Rosiglitazone 也是一种降糖剂,是噻唑烷二酮类胰岛素增敏剂。 | |||
T8780 | PPAR | ||
AMG131 (CHS 131) 是一种新型非噻唑烷二酮(TZD) 选择性过氧化物酶体增殖物激活受体 (PPAR) γ 调节剂,可用于治疗 2 型糖尿病。 | |||
T4S1173 | Sirtuin PPAR | ||
Agrimol B 是从仙鹤草中分离得到的一种多酚衍生物,可抑制脂肪形成,降低PPARγ的表达,诱导SIRT1易位和表达。 | |||
T6646 | Ferroptosis TRP/TRPV Channel PPAR Autophagy | ||
Rosiglitazone hydrochloride (BRL-49653 HCl) 是一种降血糖药物,通过与脂肪细胞中的 PPAR 受体结合来刺激胰岛素分泌。它对 PPARγ1、PPARγ2 和 PPARγ 的EC50值分别为 30 nM、100 nM 和 60 nM。它也是TRPC5的激活剂和TRPM3的抑制剂。 | |||
T62646 | |||
Pparδ agonist 5 是一种选择性的、口服具有活力的 PPARδ 激动剂,其 EC50 为 0.335 μM,选择性好于 GW0742。Pparδ agonist 5 对体内骨密度和微结构的改善具有促进作用。 | |||
T78806 | PPAR | ||
PPARδ agonist9 (compound 21) 作为PPARδ激动剂,展现出EC50为3.6 nM的活性。在体内实验中,PPARδ agonist9能有效降低小鼠血清中MCP-1水平,并在LDLr-KO模型中显著抑制动脉粥样硬化的发展,其抑制率达50-60%。 | |||
T62968 | |||
PPARα/δ agonist 1 是一种有效的 PPARα/PPARδ 双重激动剂,对 PPARα和 PPARδ 的 EC50 值分别为 7.0 nM 和 8.4 nM。PPARα/δ agonist 1 对 PPARγ 表现出很高的选择性 (EC50: 1316.1 nM)。PPARα/δ agonist 1 具有潜力进行非酒精性脂肪性肝炎的研究。 | |||
T62266 | |||
PPARα agonist 1 是一种完整的、有效的 PPARα激动剂。 | |||
T62277 | |||
Pparδ agonist 8 是一种 Pparδ 的有效激动剂。其中过氧化物酶体增殖物激活受体 (PPAR) 属于核内受体转录因子超家族,在体内代谢稳态、炎症、细胞生长和分化的调节中具有关键作用。Pparδ agonist 8 具有潜力进行非酒精性脂肪肝 (NAFLD) 的研究。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02575 | PPAR gamma/PPARG Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
Peroxisome proliferator-activated receptor gamma (PPARG), a nuclear hormone receptor, plays a critical role in the lipid and glucose homeostasis, adipocyte differentiation, as well as intracellular insulin-signaling events. The peroxisome proliferator-activated receptor gamma (PPARgamma) regulates osteoblast and osteoclast differentiation, and is the molecular target of thiazolidinediones (TZDs), insulin sensitizers that enhance glucose utilization and adipocyte differentiation. Peroxisome proliferator-activated receptor gamma (PPARG) is a transcription factor involved in atherosclerosis and related diseases. Peroxisome proliferator-activated receptor gamma (PPARG) plays an important role in the pathogenesis and maintenance of essential hypertension (EH).The functional single nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma (PPARG) gene were predicted to be correlated with the susceptibility of colorectal cancer (CRC).
|
|||||
TMPH-02827 | PPAR gamma Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels.
|
|||||
TMPY-06830 | PPAR alpha/PPARA Protein, Human, Recombinant (His) | Human | E. coli | ||
Peroxisome proliferators include hypolipidemic drugs, herbicides, leukotriene antagonists, and plasticizers; this term arises because they induce an increase in the size and number of peroxisomes. Peroxisomes are subcellular organelles found in plants and animals that contain enzymes for respiration and for cholesterol and lipid metabolism. The action of peroxisome proliferators is thought to be mediated via specific receptors, called PPARs, which belong to the steroid hormone receptor superfamily. PPARs affect the expression of target genes involved in cell proliferation, cell differentiation and in immune and inflammation responses. Three closely related subtypes (alpha, beta/delta, and gamma) have been identified. This gene encodes the subtype PPAR-alpha, which is a nuclear transcription factor. Multiple alternatively spliced transcript variants have been described for this gene, although the full-length nature of only two has been determined.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPH-03711 | PPAR gamma Protein, Xenopus laevis, Recombinant (His) | Xenopus laevis | E. coli | ||
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. May play a role in the regulation of circadian rhythm.
|
|||||
TMPY-06837 | PPAR alpha/PPARA Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Peroxisome proliferators include hypolipidemic drugs, herbicides, leukotriene antagonists, and plasticizers; this term arises because they induce an increase in the size and number of peroxisomes. Peroxisomes are subcellular organelles found in plants and animals that contain enzymes for respiration and for cholesterol and lipid metabolism. The action of peroxisome proliferators is thought to be mediated via specific receptors, called PPARs, which belong to the steroid hormone receptor superfamily. PPARs affect the expression of target genes involved in cell proliferation, cell differentiation and in immune and inflammation responses. Three closely related subtypes (alpha, beta/delta, and gamma) have been identified. This gene encodes the subtype PPAR-alpha, which is a nuclear transcription factor. Multiple alternatively spliced transcript variants have been described for this gene, although the full-length nature of only two has been determined.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|